公告显示，Finer持有公司股份7043.79万股，占公司总股本的15.5375%。上述股份来源为公司首次公开 发行前取得的股份，已于2025年8月25日解除限售并上市流通。 北京商报讯（记者 丁宁）2月9日晚间，宣泰医药（688247）发布公告称，因自身资金需求，公司股东 Finer Pharma Inc.（以下简称"Finer"）计划根据市场情况拟通过集中竞价或大宗交易的方式减持其所持 有的公司股份数量合计不超过906.68万股，拟减持股份数量占公司总股本的比例不超过2%。 ...

Core Viewpoint - Qianjin Pharmaceutical (600479) reported a slight increase in revenue and a significant rise in net profit for the year 2025, indicating stable performance and growth potential in the pharmaceutical sector [1] Financial Performance - The company achieved an operating revenue of 3.635 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders reached 288 million yuan, showing a year-on-year increase of 24.74% [1] Growth Drivers - The growth in performance is primarily attributed to stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results as they were included in the consolidated financial statements starting from October and November 2025, respectively [1]

Core Viewpoint - Yuan Dong Bio (688513) announced that its wholly-owned subsidiary Chengdu Youluo Biotechnology Co., Ltd. has initiated Phase I clinical trials for its monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first patient dosing recently completed [1] Company Summary - EP-0210 is a humanized IgG1 monoclonal antibody that targets TNF-like ligand 1A (TL1A), aiming to treat inflammatory bowel disease by effectively binding to TL1A and blocking pro-inflammatory signaling pathways [1] - The development of TL1A antibody drugs is one of the most closely watched emerging targets in the field of inflammatory bowel disease, with no similar drugs currently available on the market globally [1] Industry Summary - The fastest global development progress for TL1A-targeting drugs is being made by Merck, Sanofi, and Roche/Pfizer, all of which have TL1A antibody drugs in Phase III clinical trials [1] - In China, companies such as 3SBio, ZhiXiang JinTai, and HuaShen ZhiYao have also entered Phase I clinical trials for similar TL1A-targeting drugs [1]

值得一提的是，萃华珠宝2月7日披露公告称，公司股票于2月9日起停牌一天，于2月10日起复牌，复牌 后公司股票被实施其他风险警示。公司股票被实施其他风险警示后，股票简称由"萃华珠宝"变为"ST萃 华"，公司证券代码不变，仍为"002731"，公司股票日涨跌幅限制为5%。 萃华珠宝表示，目前公司部分经营活动和业务尚能开展。立案调查期间，公司将积极配合证监会的相关 调查工作，并严格按照相关法律法规的规定和监管要求及时履行信息披露义务。 北京商报讯（记者 马换换 李佳雪）2月9日晚间，萃华珠宝（002731）披露公告称，公司于近日收到证 监会下发的《立案告知书》，因公司涉嫌信息披露违法违规，证监会决定对公司立案。 ...

北京商报讯（记者 丁宁）2月9日晚间，万泰生物（603392）发布公告称，公司董事长邱子欣计划自公 告披露之日起15个交易日后的3个月内通过集中竞价交易方式减持公司股份不超过500万股（即不超过公 司总股本的0.3954%）。 公告显示，邱子欣持有公司股份4484.68万股，占公司总股本的3.5469%，减持所得金额将捐赠给厦门大 学教育发展基金会、福建省厦门第一中学，用于支持厦门大学、福建省厦门第一中学教育事业的建设和 发展。 ...

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), received approval from the National Medical Products Administration for the clinical trial application of its injectable drug GenSci136, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a self-developed Class 1 biological product [1] - The clinical trial application for GenSci136 has been approved for use in treating IgAN and generalized myasthenia gravis [1]

温氏股份加入宠物食品混战。近日，温氏股份发布公告，公司全资子公司广东温氏投资有限公司（以下简称"温氏投资"）拟受让青岛双安生物科技有限公司 （以下简称"青岛双安"）部分股权并向其进行增资，进而切入宠物食品这一细分赛道。 公告显示，此次交易，温氏投资拟投资不超过1.47亿元。其中，温氏投资拟受让温润农科壹号（珠海）创业投资基金合伙企业（有限合伙）等4名交易对手 持有的青岛双安合计1486.84万元的注册资本，交易对价为4438.54万元。同时，温氏投资拟以1.03亿元认购青岛双安新增注册资本3445.79万元。交易完成 后，温氏投资将持有青岛双安48.18%的股权，成为其第一大股东。 公开信息显示，青岛双安是一家从事宠物食品业务的公司，成立于2010年，业务涉及宠物食品、宠物保健品研发生产及供应链服务和销售渠道运营等，打造 了黑鼻头、猫博士等自有品牌。2025年，青岛双安实现营收4.07亿元，净利润为1216.6万元。 对于此次投资，温氏股份称，旨在继续巩固现有主业优势的基础上，积极探索并布局具备协同效应及战略价值的优质细分赛道，提升公司可持续发展能力与 抗风险能力。这一选择或与其主业承压有关，业绩预告显示，由 ...

Core Viewpoint - Under Armour reported a revenue of $1.33 billion for Q3 of FY2026, reflecting a 5% year-over-year decline, with a gross margin decrease of 3.1 percentage points to 44.4% [1][3] Revenue Performance - North American revenue declined by 10% year-over-year, marking multiple quarters of downturn in this market [3] - In contrast, international revenue grew by 3%, indicating resilience in global operations [3] - The Asia-Pacific region, including China, generated $190 million, down 5%, but the decline rate has narrowed compared to the previous year [3] Management Insights - Under Armour's management believes that the quarterly performance exceeded expectations despite overall declines [3] - CEO Kevin Plank acknowledged the brand's revitalization efforts and expressed confidence in achieving stable growth in the future [3] Strategic Focus in China - Under Armour is prioritizing investment in the Chinese market, aiming to enhance long-term growth potential through strategic focus and innovation [3][4] - Recent product launches and marketing initiatives in China include a new winter collection and sponsorship of marathon events [4] Competitive Landscape - The Chinese sports market is becoming increasingly competitive, with major brands like Nike and Adidas intensifying their presence, alongside local brands such as Anta and Xtep [5] - Analysts suggest that Under Armour needs to find new narratives to capture market share amidst growing competition [5] Development Challenges - The company faces challenges in enhancing brand influence and market share, necessitating improved marketing strategies and deeper consumer connections [6] - Emphasis on product innovation and digital transformation is critical for improving customer experience and operational efficiency [6]

北京商报讯（记者 刘四红）2月9日，人民银行官网公告称，根据《中国人民银行与英格兰银行合作备 忘录》，中国人民银行决定授权中国银行股份有限公司伦敦分行担任英国人民币清算行。 ...

据了解，本次活动将从2月15日（农历腊月廿八）持续至3月3日（农历正月十五），历时17天。市民可 通过猫眼或淘票票参与多样化的观影优惠活动。 北京商报讯（记者 和岳）2月9日，据"北京发布"消息，北京市启动"骏马贺新春 京彩中国年"2026年新 春惠民观影活动，投入近3000万元新春惠民观影补贴，覆盖全市300余家影院。 ...